Novartis anti-inflammatory drug Ilaris is approved by the US FDA: the first drug to treat adult Still’s disease (AOSD)!

The U.S. Food and Drug Administration (FDA) recently approved Novartis' anti-inflammatory drug Ilaris (Elater, generic name: canakimumab, kanazumab) for the treatment of active Still's disease, including Adult paroxysmal Still's disease (AOSD). Previously, Ilaris has been granted priority review designation (PRD) for the treatment of Still's disease. It is worth mentioning

Read More
Share :

Free Mask distribution camp this month

Donec vitae hendrerit arcu, sit amet faucibus nisl. Cras pretium arcu ex. Aenean posuere libero eu augue condimentum rhoncus. Praesent ornare tortor ac ante egestas hendrerit. Aliquam et metus pharetra, bibendum massa nec, fermentum odio. Quisque semper nunc vitae erat pellentesque, ac placerat arcu consectetur. In venenatis elit ac ultrices

Read More
Share :